2-(2-Chloroethyl)thiazole | 152482-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-Chloroethyl)thiazole
• 英文别名: 2-(2-chloroethyl)-1,3-thiazole
• CAS: 152482-98-9
• 化学式: C₅H₆ClNS
• 分子量: 147.628
• InChiKey: PVXGUTLCBDMZCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二甲胺 、 2-(2-Chloroethyl)thiazole 以 乙醇 为溶剂， 反应 7.0h， 生成 2-(2-dimethylaminoethyl)thiazole
  参考文献：
  名称：

  An approach to the design of brain-penetrating histaminergic agonists

  摘要：

  Known and novel histaminergic H-1- and H-2-receptor agonists were investigated as potentially potent and selective brain-penetrating compounds. Structural modifications were introduced in an attempt to favour passive diffusion across the blood-brain barrier by reducing hydrogen-bonding ability according to a previously developed model. While no novel compound was identified which satisfied our requirements for a brain-penetrating agonist, betahistine 14 and 2-(thiazol-2-yl)ethylamine 16 can be regarded as H-1-receptor agonists with moderate brain-penetrating ability, of potential value as pharmacological tools. A novel histamine analogue, N,N-bis-{2-[4(5)-imidazolyl]ethyl)amine 25 is reported which. although unlikely to be brain penetrant, was found to be equipotent with histamine at H-1- and H-1-receptors.

  DOI：

  10.1016/0223-5234(93)90135-2
• 作为产物：
  描述：

  2-羟乙基噻唑 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 2-(2-Chloroethyl)thiazole
  参考文献：
  名称：

  An approach to the design of brain-penetrating histaminergic agonists

  摘要：

  Known and novel histaminergic H-1- and H-2-receptor agonists were investigated as potentially potent and selective brain-penetrating compounds. Structural modifications were introduced in an attempt to favour passive diffusion across the blood-brain barrier by reducing hydrogen-bonding ability according to a previously developed model. While no novel compound was identified which satisfied our requirements for a brain-penetrating agonist, betahistine 14 and 2-(thiazol-2-yl)ethylamine 16 can be regarded as H-1-receptor agonists with moderate brain-penetrating ability, of potential value as pharmacological tools. A novel histamine analogue, N,N-bis-{2-[4(5)-imidazolyl]ethyl)amine 25 is reported which. although unlikely to be brain penetrant, was found to be equipotent with histamine at H-1- and H-1-receptors.

  DOI：

  10.1016/0223-5234(93)90135-2

文献信息

• [EN] PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS<br/>[FR] COMPOSÉS PYRIMIDINYL-PYRIDYLOXY-NAPHTYLE ET PROCÉDÉS DE TRAITEMENT DE MALADIES ET DE TROUBLES LIÉS À IRE1
  申请人：GENENTECH INC

  公开号：WO2018166528A1

  公开（公告）日：2018-09-20

  Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula (I) or (I') structure : or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula (I) or (I') compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了具有肌醇需要酶1（IRE1）调节活性或功能的嘧啶基-吡啶氧基-萘基化合物，其具有公式（I）或（I'）结构：或其立体异构体，互变异构体或药学上可接受的盐，并具有所述的取代基和结构特征。还描述了包括公式（I）或（I'）化合物的制药组合物和药物，以及使用这种IRE1调节剂的方法，单独或与其他治疗剂联合治疗介导或依赖于雌激素受体的疾病或病况。
• [EN] SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO<br/>[FR] COMPOSES INDUCTEURS DE SOMMEIL ET METHODES ASSOCIEES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005097093A1

  公开（公告）日：2005-10-20

  Compounds having the following structure: (I) including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, L1, L2 and n are as defined herein. Pharmaceutical compositions containing one or more compounds of structure (I), as well as methods relating to the use thereof, including methods for treating insomnia, inducing sleep or inducing sedation or hypnosis, are also disclosed.

  具有以下结构的化合物：(I) 包括立体异构体、前药和其药用可接受的盐，其中R1、R2a、R2b、R3、R4、R5a、R5b、L1、L2和n如本文所定义。包含一个或多个结构(I)的化合物的药物组合物，以及与其使用相关的方法，包括用于治疗失眠、诱导睡眠或诱导镇静或催眠的方法，也被披露。
• Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
  申请人：——

  公开号：US20020022622A1

  公开（公告）日：2002-02-21

  Provided are, among other things, compounds of formula I or IA, 1 . Also provided are methods of treatment with such compounds.

  提供的是公式I或IA,1的化合物，以及使用这些化合物进行治疗的方法。
• Dérivés de méthyl-4[(phényl-4 pipérazinyl-1)-2 éthyl]-5 thiazole, leur procédé de préparation et les compositions pharmaceutiques en contenant
  申请人：INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (IRCEBA)

  公开号：EP0364350B1

  公开（公告）日：1994-01-12
• THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING
  申请人：Alteon, Inc.

  公开号：EP1248615A1

  公开（公告）日：2002-10-16